Clinical Trial Update: Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

View source ↗

Summary

This completed trial compared a fixed-dose rituximab schedule (1000 mg on days 1 and 15) with the standard regimen in adults with primary immune thrombocytopeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Henri Mondor University Hospital | Conditions: Primary Immune Thrombocytopenia | Status: COMPLETED